NCT03942406View on ClinicalTrials.gov

Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 15, 2019

Primary Completion Date

February 14, 2020

Study Completion Date

June 24, 2020

Conditions
PertussisWhooping Cough
Interventions
COMBINATION_PRODUCT

BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device

Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device

Trial Locations (3)

44122

Rapid medical Research Inc, Cleveland

77375

DM Clinical Research, Tomball

84088

Advanced Clinical Research, West Jordan

Sponsors

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

ILiAD Biotechnologies

INDUSTRY